Adage Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $79.7M | Buy |
103,097
+20,651
| +25% | +$15.8M | 0.12% | 168 |
|
|
2025
Q4 | $63.6M | Sell |
82,446
-40,600
| -33% | -$27.6M | 0.1% | 203 |
|
|
2025
Q3 | $69.2M | Buy |
123,046
+27,416
| +29% | +$15.5M | 0.11% | 181 |
|
|
2025
Q2 | $50.2M | Buy |
95,630
+2,885
| +3% | +$1.61M | 0.08% | 239 |
|
|
2025
Q1 | $58.8M | Buy |
92,745
+48,396
| +109% | +$33.3M | 0.11% | 189 |
|
|
2024
Q4 | $31.6M | Sell |
44,349
-125,290
| -74% | -$105M | 0.06% | 313 |
|
|
2024
Q3 | $178M | Buy |
169,639
+7,140
| +4% | +$7.95M | 0.31% | 51 |
|
|
2024
Q2 | $171M | Buy |
162,499
+30,361
| +23% | +$29.4M | 0.32% | 52 |
|
|
2024
Q1 | $127M | Sell |
132,138
-3,511
| -3% | -$3.34M | 0.24% | 79 |
|
|
2023
Q4 | $119M | Buy |
135,649
+40,900
| +43% | +$33.7M | 0.25% | 86 |
|
|
2023
Q3 | $78M | Sell |
94,749
-43,300
| -31% | -$34M | 0.18% | 133 |
|
|
2023
Q2 | $99.2M | Sell |
138,049
-35,200
| -20% | -$27.1M | 0.22% | 113 |
|
|
2023
Q1 | $142M | Buy |
173,249
+100,927
| +140% | +$76.1M | 0.32% | 70 |
|
|
2022
Q4 | $52.2M | Buy |
72,322
+10,073
| +16% | +$7.43M | 0.12% | 200 |
|
|
2022
Q3 | $42.9M | Buy |
+62,249
| New | +$39.2M | 0.11% | 206 |
|
|
2022
Q2 | – | Sell |
-94,449
| Closed | -$66M | – | 1135 |
|
|
2022
Q1 | $66M | Sell |
94,449
-1,200
| -1% | -$759K | 0.13% | 167 |
|
|
2021
Q4 | $60.4M | Buy |
95,649
+165
| +0.2% | +$101K | 0.11% | 189 |
|
|
2021
Q3 | $57.8M | Sell |
95,484
-1,222
| -1% | -$759K | 0.11% | 184 |
|
|
2021
Q2 | $54M | Buy |
96,706
+48,300
| +100% | +$24.5M | 0.11% | 201 |
|
|
2021
Q1 | $22.9M | Sell |
48,406
-52,200
| -52% | -$25.4M | 0.05% | 404 |
|
|
2020
Q4 | $48.6M | Sell |
100,606
-1,130
| -1% | -$610K | 0.11% | 207 |
|
|
2020
Q3 | $57M | Sell |
101,736
-49,150
| -33% | -$29.8M | 0.14% | 158 |
|
|
2020
Q2 | $94.1M | Buy |
150,886
+84,808
| +128% | +$48.1M | 0.24% | 96 |
|
|
2020
Q1 | $32.3M | Buy |
+66,078
| New | +$27.3M | 0.1% | 238 |
|
|
2019
Q1 | – | Sell |
-37,021
| Closed | -$13.8M | – | 729 |
|
|
2018
Q4 | $13.8M | Sell |
37,021
-52,200
| -59% | -$19.1M | 0.04% | 428 |
|
|
2018
Q3 | $36M | Buy |
+89,221
| New | +$34M | 0.08% | 279 |
|
|
2017
Q4 | – | Sell |
-11,910
| Closed | -$5.33M | – | 740 |
|
|
2017
Q3 | $5.33M | Sell |
11,910
-46,100
| -79% | -$21.9M | 0.01% | 620 |
|
|
2017
Q2 | $28.5M | Buy |
+58,010
| New | +$25.4M | 0.07% | 341 |
|
|
2017
Q1 | – | Sell |
-13,310
| Closed | -$4.89M | – | 739 |
|
|
2016
Q4 | $4.89M | Sell |
13,310
-107,044
| -89% | -$40.7M | 0.01% | 609 |
|
|
2016
Q3 | $48.4M | Buy |
120,354
+75,180
| +166% | +$30.2M | 0.13% | 212 |
|
|
2016
Q2 | $15.8M | Sell |
45,174
-6,100
| -12% | -$2.35M | 0.04% | 419 |
|
|
2016
Q1 | $18.5M | Sell |
51,274
-64,930
| -56% | -$26.8M | 0.05% | 377 |
|
|
2015
Q4 | $63.1M | Buy |
116,204
+2,692
| +2% | +$1.46M | 0.17% | 165 |
|
|
2015
Q3 | $52.8M | Buy |
113,512
+48,600
| +75% | +$26.1M | 0.15% | 183 |
|
|
2015
Q2 | $33.1M | Buy |
64,912
+18,000
| +38% | +$8.78M | 0.08% | 303 |
|
|
2015
Q1 | $21.2M | Sell |
46,912
-25,000
| -35% | -$10.6M | 0.05% | 407 |
|
|
2014
Q4 | $29.5M | Buy |
71,912
+27,132
| +61% | +$10.7M | 0.07% | 330 |
|
|
2014
Q3 | $16.1M | Sell |
44,780
-194,300
| -81% | -$65.1M | 0.04% | 439 |
|
|
2014
Q2 | $67.5M | Sell |
239,080
-63,600
| -21% | -$18.8M | 0.17% | 170 |
|
|
2014
Q1 | $90.9M | Buy |
302,680
+181,800
| +150% | +$56M | 0.25% | 123 |
|
|
2013
Q4 | $33.3M | Sell |
120,880
-188,840
| -61% | -$54.3M | 0.09% | 288 |
|
|
2013
Q3 | $96.9M | Buy |
309,720
+14,950
| +5% | +$3.93M | 0.28% | 99 |
|
|
2013
Q2 | $66.3M | Buy |
+294,770
| New | +$68.6M | 0.2% | 147 |
|
Other funds holding REGN
VCM
N
Adage Capital Partners's REGN Position: Q1 2026 in Review
Adage Capital Partners increased its Regeneron Pharmaceuticals (REGN) stake by 25% in Q1 2026, buying an estimated $15.8M and bringing the position to 103,097 shares worth $79.7M. The position accounts for 0.12% of the portfolio, ranked #168.
Adage Capital Partners first reported a position in REGN in Q2 2013 and has held it in 43 quarters since. The position peaked at $178M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Adage Capital Partners held 103,097 shares of Regeneron Pharmaceuticals worth $79.7M as of Q1 2026.
- Adage Capital Partners bought 20,651 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $15.8M.
- Regeneron Pharmaceuticals made up 0.12% of Adage Capital Partners's portfolio in Q1 2026, its #168 holding.
- Adage Capital Partners first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Adage Capital Partners's Regeneron Pharmaceuticals position peaked at $178M in Q3 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.